Results 231 to 240 of about 36,124 (280)
Some of the next articles are maybe not open access.
Chasing ctDNA in Patients With Sarcoma
American Society of Clinical Oncology Educational Book, 2020Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Catherine C, Coombs +2 more
openaire +2 more sources
ctDNA as a cancer biomarker: A broad overview
Critical Reviews in Oncology/Hematology, 2020 Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been
Valéria Pereira Ferrer
exaly +4 more sources
Dynamic Treatment Stratification Using ctDNA
2019An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana, Vidal +2 more
openaire +2 more sources
ctDNA-Monitoring beim frühen Brustkrebs
Onkologische Welt, 2021Der Nachweis von zirkulierender Tumor-DNA (ctDNA) nach neoadjuvanter Chemotherapie mit oder ohne Pembrolizumab wurde in der Studie I-SPY 2 bei Hochrisikopatientinnen mit frühem Brustkrebs als Biomarker für Ansprechen und fernmetastasenfreies Überleben (RFS) identifiziert.
openaire +1 more source
ctDNA als Prognosemarker beim DLBCL
Im Fokus Onkologie, 2019Zirkulierende Tumor-DNA (ctDNA) wird derzeit immer wieder als prognostischer Marker diskutiert. Gerade beim diffusen groszelligen B-Zell-Lymphom (DLBCL) ware ein solcher von grosem Wert, da die Behandlungsergebnisse immer noch schwer vorherzusagen sind.
Christian Behrend +2 more
openaire +1 more source
Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Cancer Discovery, 2021Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of ...
openaire +2 more sources
Enrichment and Analysis of ctDNA
2019ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire +3 more sources
Methods for Measuring ctDNA in Lymphomas
2018Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide +3 more
openaire +3 more sources
Review ctDNA and Breast Cancer
2019In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely fundamental research to nearby daily use for treatment selection and drug-resistance assessment. Indeed, technical advances and widespread use of next-generation sequencing or digital PCR allowed for detection of very low amount of tumor DNA in bloodstream.
openaire +3 more sources